Core Thesis - Rush Enterprises, Inc. is viewed positively as a stock investment opportunity, with a current share price of $62.39 and trailing and forward P/E ratios of 19.08 and 11.07 respectively [1] Company Overview - Rush Enterprises is the largest integrated retailer of commercial vehicles and related services in the U.S., operating over 155 franchised dealerships across 23 states, serving Class 8 and Class 4–7 markets with market shares of 6% and 5% respectively [3] - The company primarily sells vehicles from manufacturers such as Peterbilt, International, Hino, Ford, and Isuzu [3] Revenue Generation - Beyond vehicle sales, Rush generates significant revenue from parts and service, which now account for the majority of EBIT, supported by a proprietary parts distribution network covering approximately 65% of parts sales [4] - Managed accounts, which include larger fleets and repair shops, have shown consistent growth through economic cycles, enhancing the company's resilience during downturns [5] Strategic Positioning - Rush has established strong relationships with OEMs, particularly Peterbilt and International, allowing for an expanded dealership network and aftermarket capabilities, which provide significant bargaining power [6] - The company has improved its absorption rate to 133%, insulating it from the cyclical nature of truck sales and enhancing overall profitability [5] Market Outlook - Strong secular tailwinds such as fleet consolidation, aging trucks, and increasing complexity position Rush to benefit from a future recovery in freight volumes [7] - The company is trading at a low valuation of 8.4x mid-cycle earnings, with a proven track record of EPS growth and shareholder-aligned capital allocation, presenting a compelling low-risk, high-upside investment opportunity [7]

Group 1 - The 351 exchange strategy allows stock portfolios with years of appreciation to be transferred to ETFs without triggering capital gains taxes, gaining traction among asset managers [1][2] - Asset managers are increasingly incorporating 351 exchange provisions into new ETFs, with some firms moving to lower initial investment minimums, such as Alpha Architect's fund with a minimum of $150,000 [2][3] - Notable firms preparing funds with 351 provisions include American Century's Avantis Investors, which launched the Total Equity Markets ETF (AVTM) [3] Group 2 - The rise of 351 exchanges has attracted attention from Congress and the US Treasury, which may issue guidance or restrictions on these exchanges in the future [4] - Firms like Ritzholtz Wealth and Polen Capital are launching new ETFs, with Ritzholtz's Goaltender ETF (GTND) being its first, and Polen Capital filing for US SMID Cap Growth and 5Perspectives Growth Opportunities ETFs [5]

Core Insights - McKesson reported $97.83 billion in revenue for the quarter ended June 2025, a year-over-year increase of 23.4% [1] - The EPS for the same period was $8.26, compared to $7.88 a year ago, with a surprise of +0.36% over the consensus estimate [1] Revenue Breakdown - U.S. Pharmaceutical revenue was $89.95 billion, exceeding the average estimate of $87.36 billion, with a year-over-year change of +25.4% [4] - Prescription Technology Solutions revenue reached $1.43 billion, surpassing the $1.35 billion estimate, reflecting a +15.6% year-over-year change [4] - International revenue was $3.74 billion, slightly above the $3.67 billion estimate, representing a +1.3% change year-over-year [4] - Medical-Surgical Solutions revenue was $2.7 billion, matching the estimate, with a +2.5% year-over-year change [4] Adjusted Operating Profit - Adjusted Operating Profit for U.S. Pharmaceutical was $950 million, below the average estimate of $965.96 million [4] - Adjusted Operating Profit for International was $99 million, slightly below the $100.22 million estimate [4] - Adjusted Operating Profit for Medical-Surgical Solutions was $244 million, exceeding the estimate of $215.97 million [4] - Adjusted Operating Profit for Prescription Technology Solutions was $269 million, above the $249.95 million estimate [4] - Adjusted Operating Profit for Corporate was -$138 million, worse than the average estimate of -$108.6 million [4] Stock Performance - McKesson shares returned -2% over the past month, while the Zacks S&P 500 composite increased by +0.5% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential outperformance in the near term [3]

Core Viewpoint - Conagra Brands (CAG) is expected to report a decline in quarterly earnings and revenues, with analysts adjusting their estimates downward over the past month [1][2]. Financial Performance - Quarterly earnings are predicted to be $0.59 per share, a decrease of 3.3% year-over-year [1]. - Revenues are forecasted at $2.85 billion, reflecting a year-over-year decrease of 1.8% [1]. Analyst Revisions - The consensus EPS estimate has been adjusted downward by 2% over the past 30 days, indicating a reassessment by covering analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and stock price performance [3]. Sales Projections - 'Sales- Grocery & Snacks' are expected to reach $1.18 billion, showing a year-over-year increase of 0.7% [5]. - 'Sales- Foodservice' is forecasted at $282.84 million, indicating a decline of 2.9% from the prior year [5]. - 'Sales- International' is projected to be $228.22 million, reflecting a significant decrease of 14.5% year-over-year [5]. Operating Profit Estimates - 'Adjusted Operating Profit (loss)- Grocery & Snacks' is estimated at $256.07 million, slightly up from $255.40 million a year ago [8]. - 'Adjusted Operating Profit (loss)- Refrigerated & Frozen' is projected at $171.73 million, down from $189.70 million in the same quarter last year [8]. - 'Adjusted Operating Profit (loss)- Foodservice' is expected to be $38.03 million, down from $39.70 million year-over-year [9]. - 'Adjusted Operating Profit (loss)- International' is estimated at $29.74 million, slightly up from $28.90 million a year ago [9]. Stock Performance - Over the past month, shares of Conagra Brands have declined by 5.7%, contrasting with a 5.2% increase in the Zacks S&P 500 composite [10]. - Conagra Brands currently holds a Zacks Rank 5 (Strong Sell), indicating potential underperformance in the near future [10].

Core Insights - McKesson reported revenue of $90.82 billion for the quarter ended March 2025, reflecting a 19% increase year-over-year, with EPS at $10.12 compared to $6.18 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate of $93.7 billion by 3.08%, while the EPS exceeded the consensus estimate of $9.81 by 3.16% [1] Revenue Breakdown - U.S. Pharmaceutical revenue was $83.17 billion, a 20.9% increase year-over-year, but below the average estimate of $85.79 billion [4] - Prescription Technology Solutions revenue reached $1.34 billion, up 13.5% year-over-year, slightly below the average estimate of $1.36 billion [4] - International revenue was $3.46 billion, showing a year-over-year decline of 2.5%, compared to the average estimate of $3.55 billion [4] - Medical-Surgical Solutions revenue was $2.85 billion, a 0.6% increase year-over-year, exceeding the average estimate of $2.79 billion [4] Adjusted Operating Profit - Adjusted Operating Profit for U.S. Pharmaceutical was $1.05 billion, matching the average estimate [4] - Adjusted Operating Profit for International was $102 million, surpassing the average estimate of $96.42 million [4] - Adjusted Operating Profit for Corporate was -$165 million, slightly worse than the average estimate of -$160.18 million [4] - Adjusted Operating Profit for Prescription Technology Solutions was $285 million, exceeding the average estimate of $267.80 million [4] - Adjusted Operating Profit for Medical-Surgical Solutions was $285 million, slightly above the average estimate of $283.33 million [4] Stock Performance - McKesson's shares returned +7.5% over the past month, underperforming compared to the Zacks S&P 500 composite's +11.3% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - H&R Block (HRB) is expected to report quarterly earnings of $5.12 per share, reflecting a year-over-year increase of 3.6% [1] - Anticipated revenues for the quarter are projected at $2.25 billion, which represents a 2.8% increase compared to the same quarter last year [1] - The consensus EPS estimate has remained unchanged over the past 30 days, indicating analysts' reassessment of their projections [1] Revenue Estimates - Analysts predict 'Revenues- U.S. assisted tax preparation' to be $1.60 billion, showing a year-over-year change of +4.5% [4] - 'Revenues- U.S. royalties' are expected to be $133.04 million, indicating a decline of -6.3% from the previous year [4] - 'Revenues- U.S. DIY tax preparation' is estimated to reach $202.19 million, reflecting a +1.8% change year-over-year [4] International and Other Revenue Projections - 'Revenues- International' are forecasted at $70.58 million, suggesting a +3.4% change year-over-year [5] - 'Revenues- Refund Transfers' are expected to be $116.00 million, indicating a -2.5% change from the prior year [5] - 'Revenues- Tax Identity Shield' is projected at $7.21 million, reflecting a -4.3% change year-over-year [5] Additional Revenue Insights - 'Revenues- Peace of Mind Extended Service Plan' is expected to be $16.71 million, indicating a -0.6% change [6] - 'Revenues- Interest and fee income on Emerald Advance' is projected at $19.12 million, suggesting a -9.7% change year-over-year [6] - 'Revenues- Other' is estimated to reach $12.98 million, reflecting a +7.6% change from the previous year [6] Performance and Market Position - The consensus estimate for 'Revenues- Wave' stands at $26.30 million, indicating a +11.5% change year-over-year [7] - 'Revenues- Emerald Card and Spruce' are expected to be $37.56 million, reflecting a -8.8% change from the prior year [7] - H&R Block shares have returned +12.5% over the past month, outperforming the Zacks S&P 500 composite's +11.5% change [7]